enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 325.0% in April

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 20,400 shares, a growth of 325.0% from the March 31st total of 4,800 shares. Based on an average trading volume of 10,000 shares, the days-to-cover ratio is currently 2.0 days.

enGene Trading Down 2.7 %

Shares of NASDAQ ENGNW traded down $0.02 during trading on Monday, reaching $0.72. 1,400 shares of the stock were exchanged, compared to its average volume of 10,954. enGene has a twelve month low of $0.42 and a twelve month high of $4.70. The business’s 50-day moving average price is $0.67 and its 200 day moving average price is $1.05.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.